Skip to content
Information Technology, Medical Health Aged Care

Researchers train AI to diagnose lung diseases

Charles Darwin University 2 mins read

Artificial Intelligence (AI) could become a radiologist’s best friend, with researchers training the technology to accurately diagnose pneumonia, COVID-19 and other lung diseases.

The new study by researchers from Charles Darwin University (CDU), United International University, and Australian Catholic University (ACU) on developing and training an AI model to analyse lung ultrasound videos and diagnose respiratory diseases. 

The model works by examining each video frame to find important features of the lungs and assesses the order of the video frames to understand the patterns of the lungs over time. 

The model then identifies specific patterns indicating different lung diseases and based on this information, classifies the ultrasound into a diagnosis category such as normal, pneumonia, COVID-19 and other lung diseases. 

Co-author and CDU adjunct Associate Professor Niusha Shafiabady said the model had an accuracy of 96.57 per cent, with the AI analyses verified by medical professionals. 

“The model also uses AI techniques to show radiologists why it made certain decisions, making it easier for them to trust and understand the results,” Associate Professor Shafiabady said. 

The model uses explainable AI, a method which allows human users to understand and trust the results created by machine learning algorithms.

“The explainability of the proposed model aims to increase the reliability of this approach,” Associate Professor Shafiabady said. 

“The system shows doctors why it made certain decisions using visuals like heatmaps. This interpretation technique will aid a radiologist in localising the focus area and improve clinical transparency substantially.

“This model helps doctors diagnose lung diseases quickly and accurately, supports their decision-making, saves time, and serves as a valuable training tool.”

Associate Professor Shafiabady said if fed the appropriate data, the model could be trained to identify more diseases such as tuberculosis, black lung, asthma, cancer, chronic lung disease, and pulmonary fibrosis. 

The study was led by researchers at United International University in Bangladesh, alongside CDU researchers Dr Asif KarimDr Sami AzamDr Kheng Cher YeoProfessor Friso De Boer and Associate Professor Niusha Shafiabady, who is also a researcher at ACU.

Potential avenues for research include training the model to assess other imaging, such as CT scans and x-rays. 

Automated diagnosis of respiratory diseases from lung ultrasound videos ensuring XAI: an innovative hybrid model approach was published in journal Frontiers in Computer Science


Contact details:

Raphaella Saroukos she/her
Research Communications Officer
Marketing, Media & Communications
Larrakia Country
T: +61 8 8946 6721
E: [email protected]
W: cdu.edu.au

Media

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

  • Medical Health Aged Care, Seniors Interest
  • 08/12/2025
  • 08:56
Monash University

Men and women may need different medications to avoid broken bones

A new international study, published in Osteoporosis International and led by Monash’s Centre for Medicine Use and Safety (CMUS), investigated the risks of a…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.